170 related articles for article (PubMed ID: 16002161)
1. Effects of long-term oral treatment with selective vasopressin V2 receptor antagonist (OPC-31260) on adriamycin-induced heart failure in rats.
Takeuchi M; Lee JD; Shimizu H; Ueda T
Int J Cardiol; 2006 Apr; 108(2):231-6. PubMed ID: 16002161
[TBL] [Abstract][Full Text] [Related]
2. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats.
Yamamura Y; Nakamura S; Itoh S; Hirano T; Onogawa T; Yamashita T; Yamada Y; Tsujimae K; Aoyama M; Kotosai K; Ogawa H; Yamashita H; Kondo K; Tominaga M; Tsujimoto G; Mori T
J Pharmacol Exp Ther; 1998 Dec; 287(3):860-7. PubMed ID: 9864265
[TBL] [Abstract][Full Text] [Related]
3. Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients.
Abraham WT; Shamshirsaz AA; McFann K; Oren RM; Schrier RW
J Am Coll Cardiol; 2006 Apr; 47(8):1615-21. PubMed ID: 16630999
[TBL] [Abstract][Full Text] [Related]
4. Potent aquaretic agent. A novel nonpeptide selective vasopressin 2 antagonist (OPC-31260) in men.
Ohnishi A; Orita Y; Okahara R; Fujihara H; Inoue T; Yamamura Y; Yabuuchi Y; Tanaka T
J Clin Invest; 1993 Dec; 92(6):2653-9. PubMed ID: 8254021
[TBL] [Abstract][Full Text] [Related]
5. Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist.
Serradeil-Le Gal C; Lacour C; Valette G; Garcia G; Foulon L; Galindo G; Bankir L; Pouzet B; Guillon G; Barberis C; Chicot D; Jard S; Vilain P; Garcia C; Marty E; Raufaste D; Brossard G; Nisato D; Maffrand JP; Le Fur G
J Clin Invest; 1996 Dec; 98(12):2729-38. PubMed ID: 8981918
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic and diagnostic potential of a vasopressin-2 antagonist for impaired water handling in cirrhosis.
Inoue T; Ohnishi A; Matsuo A; Kawai B; Kunihiro N; Tada Y; Koizumi F; Chau T; Okada K; Yamamura Y; Tanaka T
Clin Pharmacol Ther; 1998 May; 63(5):561-70. PubMed ID: 9630829
[TBL] [Abstract][Full Text] [Related]
7. Aquaretic effect of a potent, orally active, nonpeptide V2 antagonist in men.
Ohnishi A; Orita Y; Takagi N; Fujita T; Toyoki T; Ihara Y; Yamamura Y; Inoue T; Tanaka T
J Pharmacol Exp Ther; 1995 Feb; 272(2):546-51. PubMed ID: 7853167
[TBL] [Abstract][Full Text] [Related]
8. Comparison of two aquaretic drugs (niravoline and OPC-31260) in cirrhotic rats with ascites and water retention.
Bosch-Marcé M; Poo JL; Jiménez W; Bordas N; Leivas A; Morales-Ruiz M; Muñoz RM; Pérez M; Arroyo V; Rivera F; Rodés J
J Pharmacol Exp Ther; 1999 Apr; 289(1):194-201. PubMed ID: 10087004
[TBL] [Abstract][Full Text] [Related]
9. Antidiuretic effects of a nonpeptide vasopressin V(2)-receptor agonist, OPC-51803, administered orally to rats.
Nakamura S; Hirano T; Tsujimae K; Aoyama M; Kondo K; Yamamura Y; Mori T; Tominaga M
J Pharmacol Exp Ther; 2000 Dec; 295(3):1005-11. PubMed ID: 11082435
[TBL] [Abstract][Full Text] [Related]
10. Effects of nonpeptide vasopressin V2 antagonist tolvaptan in rats with heart failure.
Veeraveedu PT; Watanabe K; Ma M; Palaniyandi SS; Yamaguchi K; Suzuki K; Kodama M; Aizawa Y
Biochem Pharmacol; 2007 Nov; 74(10):1466-75. PubMed ID: 17720144
[TBL] [Abstract][Full Text] [Related]
11. Effects of the V(2)-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats.
Hirano T; Yamamura Y; Nakamura S; Onogawa T; Mori T
J Pharmacol Exp Ther; 2000 Jan; 292(1):288-94. PubMed ID: 10604960
[TBL] [Abstract][Full Text] [Related]
12. Effects of novel vasopressin receptor antagonists on renal function and cardiac hypertrophy in rats with experimental congestive heart failure.
Bishara B; Shiekh H; Karram T; Rubinstein I; Azzam ZS; Abu-Saleh N; Nitecki S; Winaver J; Hoffman A; Abassi ZA
J Pharmacol Exp Ther; 2008 Aug; 326(2):414-22. PubMed ID: 18467593
[TBL] [Abstract][Full Text] [Related]
13. Lithium effectively complements vasopressin V2 receptor antagonist in the treatment of hyponatraemia of SIADH rats.
Kazama I; Arata T; Michimata M; Hatano R; Suzuki M; Miyama N; Sanada S; Sato A; Satomi S; Ejima Y; Sasaki S; Matsubara M
Nephrol Dial Transplant; 2007 Jan; 22(1):68-76. PubMed ID: 16702208
[TBL] [Abstract][Full Text] [Related]
14. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial.
Gheorghiade M; Niazi I; Ouyang J; Czerwiec F; Kambayashi J; Zampino M; Orlandi C;
Circulation; 2003 Jun; 107(21):2690-6. PubMed ID: 12742979
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the water diuretic activity of kappa receptor agonists and a vasopressin receptor antagonist in dogs.
Brooks DP; Valente M; Petrone G; Depalma PD; Sbacchi M; Clarke GD
J Pharmacol Exp Ther; 1997 Mar; 280(3):1176-83. PubMed ID: 9067301
[TBL] [Abstract][Full Text] [Related]
16. Characterization of RWJ-351647, a novel nonpeptide vasopressin V2 receptor antagonist.
Gunnet JW; Matthews JM; Maryanoff BE; de Garavilla L; Andrade-Gordon P; Damiano B; Hageman W; Look R; Stahle P; Streeter AJ; Wines PG; Demarest KT
Clin Exp Pharmacol Physiol; 2006 Apr; 33(4):320-6. PubMed ID: 16620295
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites.
Guyader D; Patat A; Ellis-Grosse EJ; Orczyk GP
Hepatology; 2002 Nov; 36(5):1197-205. PubMed ID: 12395330
[TBL] [Abstract][Full Text] [Related]
18. Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure.
Veeraveedu PT; Watanabe K; Ma M; Palaniyandi SS; Yamaguchi K; Kodama M; Aizawa Y
Biochem Pharmacol; 2008 Mar; 75(6):1322-30. PubMed ID: 18179782
[TBL] [Abstract][Full Text] [Related]
19. Vasopressin antagonist improves renal function in a rat model of pneumoperitoneum.
Dolgor B; Kitano S; Yoshida T; Bandoh T; Ninomiya K; Matsumoto T
J Surg Res; 1998 Oct; 79(2):109-14. PubMed ID: 9758724
[TBL] [Abstract][Full Text] [Related]
20. Intravenous administration of conivaptan hydrochloride improves cardiac hemodynamics in rats with myocardial infarction-induced congestive heart failure.
Wada K; Fujimori A; Matsukawa U; Arai Y; Sudoh K; Yatsu T; Sasamata M; Miyata K
Eur J Pharmacol; 2005 Jan; 507(1-3):145-51. PubMed ID: 15659304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]